

# Division of Dermatology, Grand

**May 7, 2024 at 8:00 AM – 9:00 AM**

**UCLA Ronald Reagan Medical Center**

## Division of Dermatology, Grand Rounds - 4/30/2024

### Overview

The UCLA Dermatology Grand Rounds is the core meeting of the division. This series trains attendees to evaluate and manage challenging patients. It provides an opportunity for presentation of challenging patients from the division. Attendees are exposed to cutting-edge basic science and clinical research. The latest literature is reviewed, keeping attendees up to date on issues such as pathogenesis, therapeutics, epidemiology, patient safety, and clinical competency. It invites nationally and internationally renowned speakers to expose the audience to outside expertise. It serves as a resource for the audience to keep current on knowledge, competency, and clinical practice in order to better serve patients with skin diseases.


### Learning Objectives

- 1 Generate appropriate differential diagnoses of live patients presented.
- 2 Interpret laboratory and histological information, including review of pathology slides from skin biopsies taken from presented patients.
- 3 Provide management guidance to the physician presenting the patient.
- 4 Follow-up on patients presented in prior case reviews.
- 5 Describe current basic-science research in dermatology.
- 6 Discuss current clinical research in dermatology.
- 7 Review and analyze the etiology, pathogenesis and therapy of dermatologic topics.
- 8 Discuss the use of new technology in dermatology and utilize appropriately.
- 9 Improve patient outcomes.
- 10 Improve clinical practice.
- 11 Provide board-relevant information to residents.

### Target Audience

Specialties – Dermatology, Dermatopathology, General Dermatology, Micrographic Dermatologic Surgery, Pediatric Dermatology  
 Professions – Physician, Fellow, Laboratory, Resident, Scientist/ Researcher

### Accreditation Statement



The David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### Credit Designation Statements

The David Geffen School of Medicine at UCLA designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Disclosure Statement

The individuals below have been identified as having a position to influence the content of this educational activity. As such, they have disclosed the absence or presence of a relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships for these individuals have been mitigated.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
--------------------	-------------------------------	---

Marcia Hogeling, MD	Activity Administrator	Nothing to disclose - 02/09/2024
Kyle Cheng, MD	Course Director	Stocks or stock options, excluding diversified mutual funds-Cabaletta Consulting Fee-Boehringer Ingelheim Pharmaceuticals, Inc. (Relationship has ended) Stocks or stock options, excluding diversified mutual funds-Arcutis - 01/26/2024
Christopher Song, BA	Activity Administrator	Nothing to disclose - 01/26/2024
Julie Lopez, Other	Activity Administrator	Nothing to disclose - 01/11/2024
Kimberly Valencia	CCPD Staff	Nothing to disclose - 12/20/2023
John E Harris, MD, PhD	Faculty	Consulting Fee-AbbVie (Incorporated) AbbVie (Incorporated) Paid consultant-Aldena Therapeutics Other: Founder-Aldena Therapeutics Other: Equity-Aldena Therapeutics Consulting Fee-Almirall Paid consultant-Alys Pharmaceuticals Other: Founder-Alys Pharmaceuticals Other: Equity-Alys Pharmaceuticals Consulting Fee-Avoro Consulting Fee-Bain Capital Grant or research support-Barinthus Bio NA Grant or research support-Cour Pharma Paid consultant-Granular Therapeutics, Inc Consulting Fee-Incyte Corporation Incyte Corporation Grant or research support-Incyte Corporation Incyte Corporation Other: Equity-Incyte Corporation Incyte Corporation Paid consultant-Klirna Therapeutics Other: Founder-Klirna Therapeutics Consulting Fee-Matchpoint Therapeutics Grant or research support-NexImmune Paid consultant-NIRA Biosciences Other: Founder-NIRA Biosciences Other: Equity-NIRA Biosciences Other: Equity-Rheos Medicines Paid consultant-Vimela Therapeutics Other: Founder-Vimela Therapeutics Consulting Fee-Vividion - 04/10/2024

### Commercial Support

This activity has not received commercial support.

### Connect with Us

Center for Continuing Medical Education (CCPD)

[ccpd@mednet.ucla.edu](mailto:ccpd@mednet.ucla.edu)

(310) 794-2620